Federal Register / Vol. 75, No. 191 / Monday, October 4, 2010 / Notices 61143 

Participation Agreement at 

approximately $115 million. 

VI. The Proposed Complaint 

The Commission’s Complaint alleges 

that TCCC and DPSG are direct 

competitors in the highly concentrated 

and difficult to enter (a) branded 

concentrate and (b) branded directstore-delivered carbonated soft drink 

markets. The concentrate market is 

national, and the branded soft drink 

markets are local. Total United States 

sales of concentrate is about $9 billion, 

and total United States sales of 

carbonated soft drinks, measured at 

retail, is about $70 billion. 

To carry out the distribution activities 

currently undertaken by the bottler and 

contemplated under the license 

agreement, DPSG will need to provide 

commercially sensitive confidential 

information about its marketing plans to 

CCR, the newly created TCCC bottler 

subsidiary. DPSG currently provides 

this sort of information to CCE in order 

for it to perform its bottler or 

distribution functions. The Commission 

is concerned that TCCC’s access to this 

information could enable it to use the 

information in ways that could impair 

DPSG’s ability to compete and 

ultimately injure competition by 

weakening a competitor or facilitating 

coordination in the industry. The 

Complaint alleges that TCCC’s access to 

DPSG’s confidential information could 

eliminate competition between TCCC 

and DPSG, increase the likelihood that 

TCCC may unilaterally exercise market 

power, and facilitate coordinated 

interaction in the industry. 

VII. The Proposed Consent Order 

Under the proposed Consent Order, to 

remedy the alleged competitive concern 

associated with access to the DPSG 

commercially sensitive confidential 

information, TCCC will be required to 

set up a ‘‘firewall’’ to ensure that persons 

at TCCC who may be in a position to use 

the DPSG commercially sensitive 

information in ways that may injure 

DPSG and/or facilitate coordination will 

not be allowed access to such 

information. Persons at TCCC who are 

assigned to perform traditional ‘‘bottler 

functions’’– the kinds of functions that 

CCE have historically performed for 

DPSG – will be permitted access to the 

DPSG information. Persons responsible 

for ‘‘concentrate-related functions’’– the 

kinds of functions that TCCC engaged in 

as a competitor of DPSG when both had 

their brands distributed by CCE – will 

not be permitted access to the DPSG 

information. 

The proposed Consent Agreement 

provides for the appointment of a 

monitor to assure TCCC’s compliance 

with the Consent Order. The monitor 

will have a fiduciary responsibility to 

the Commission. The monitor will be 

appointed for a five (5) year term, but 

the Commission may extend or modify 

the term as appropriate. 

The proposed Consent Agreement 

contains a prior notice provision for 

subsequent acquisitions by TCCC of its 

franchised bottlers that also are licensed 

to distribute DPSG products. Under the 

order, TCCC will be required to give the 

Commission forty-five (45) advance 

notice of a proposed acquisition that is 

not subject to the Hart-Scott-Rodino Act 

and provide the Commission with all 

management documents relating to the 

proposed acquisition. If the 45-day 

period expires without Commission 

action, TCCC will be permitted to 

consummate the proposed acquisition 

and use DPSG confidential information 

in the territories of the newly acquired 

bottler as specified in this order. The 

standard Hart-Scott-Rodino procedures 

and time periods would continue to 

apply for Hart-Scott-Rodino reportable 

transactions. 

The order, like the DPSG-TCCC 

license agreement, will have a term of 

twenty (20) years. 

VIII. Opportunity for Public Comment 

The Consent Agreement has been 

placed on the public record for thirty 

(30) days for receipt of comments from 

interested persons. Comments received 

during this period will become part of 

the public record. After thirty days, the 

Commission will again review the 

proposed Consent Agreement, as well as 

the comments received, and will decide 

whether it should withdraw from the 

Consent Agreement or make final the 

Decision and Order. 

By accepting the Consent Agreement 

subject to final approval, the 

Commission anticipates that the 

competitive problem alleged in the 

Complaint will be resolved. The 

purpose of this analysis is to invite and 

facilitate public comment concerning 

the Consent Agreement. It is not 

intended to constitute an official 

interpretation of the proposed Consent 

Agreement, nor is it intended to modify 

the terms of the Decision and Order in 

any way. 

By direction of the Commission, 

Commissioner Ramirez recused. 

Donald S. Clark, 

Secretary. 

[FR Doc. 2010–24838 Filed 10–1–10; 12:10 pm] 

BILLING CODE 6750–01–S 

GOVERNMENT ACCOUNTABILITY 

OFFICE 

Financial Management and Assurance; 

Government Auditing Standards 

Correction 

In notice document 2010–23374 

beginning on page 57274 in the issue of 

Monday, September 20, 2010 make the 

following corrections: 

1. On page 57275, in the first column, 

under the ADDRESSES section, in the 

second line, ‘‘(GAO–1O–853G)’’ should 

read ‘‘(GAO–10–853G)’’. 

2. On the same page, in the same 

column, under the ADDRESSES section, 

in the third and fourth lines, ‘‘http://

www.gao.gov/govaud/vbkO1.htm.’’ 

should read ‘‘http://www.gao.gov/

govaud/ybk01.htm.’’. 

3. On the same page, in the same 

column, under the SUPPLEMENTARY

INFORMATION section, in the seventh line, 

‘‘yeJlowbookgao.gov’’ should read 

‘‘yellowbook@gao.gov.’’ 

[FR Doc. C1–2010–23374 Filed 10–1–10; 8:45 am] 

BILLING CODE 1505–01–D 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the Advisory Committee on 

Blood Safety and Availability 

AGENCY: Office of the Assistant 

Secretary for Health, Office of the 

Secretary, Department of Health and 

Human Services. 

ACTION: Notice. 

SUMMARY: As stipulated by the Federal 

Advisory Committee Act, the U.S. 

Department of Health and Human 

Services is hereby giving notice that the 

Advisory Committee on Blood Safety 

and Availability (ACBSA) will hold a 

meeting. The meeting will be open to 

the public. 

DATES: The meeting will take place 

Thursday, November 4, and Friday, 

November 5, 2010, from 8:30 a.m. to 5 

p.m. 

ADDRESSES: The Universities at Shady 

Grove, 9630 Gudelsky Drive, Rockville, 

Maryland 20850, Phone: 301–738–6000. 

FOR FURTHER INFORMATION CONTACT: Jerry 

A. Holmberg, PhD, Executive Secretary, 

Advisory Committee on Blood Safety 

and Availability, Office of the Assistant 

Secretary for Health, Department of 

Health and Human Services, 1101 

Wootton Parkway, Suite 250, Rockville, 

MD 20852, (240) 453–8803, FAX (240) 

453–8456, e-mail ACBSA@hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

Advisory Committee on Blood Safety 


jlentini on DSKJ8SOYB1PROD with NOTICES
61144 Federal Register / Vol. 75, No. 191 / Monday, October 4, 2010 / Notices 

and Availability provides advice to the 

Secretary and the Assistant Secretary for 

Health on a range of policy issues that 

includes (1) definition of public health 

parameters around safety and 

availability of the blood supply and 

blood products, (2) broad public health, 

ethical and legal issues related to 

transfusion and transplantation safety, 

and (3) the implications for safety and 

the availability of various economic 

factors affecting product cost and 

supply. 

In keeping with its established 

mission, the ACBSA will be asked to 

review and comment on previous 

ACBSA recommendations including 

elements of a strategic plan for 

transfusion and transplantation safety. 

The review is intended to align the 

transfusion and transplantation safety 

initiatives to the Secretary’s Strategic 

Initiatives and Key Inter-Agency 

Collaborations: (http://www.hhs.gov/

secretary/about/secretarialstrategic

initiatives2010.pdf). 

The Committee will also be asked to 

comment and make recommendations 

on prioritizing previous and outstanding 

recommendations in light of the 

Assistant Secretary for Health’s mission 

statement: ‘‘Mobilizing Leadership in 

Science and Prevention for a Healthier 

Nation’’ and strategic priorities: Creating 

Better Systems of Prevention; 

Eliminating Health Disparities and 

Achieving Health Equity; and Making 

Healthy People Come Alive for all 

Americans. 

The public will have opportunity to 

present their views to the Committee on 

both meeting days. A public comment 

session has been scheduled for 

November 5, 2010. Comments will be 

limited to five minutes per speaker and 

must be pertinent to the discussion. Preregistration is required for participation 

in the public comment session. Any 

member of the public who would like to 

participate in this session is encouraged 

to contact the Executive Secretary at 

his/her earliest convenience to register 

for time (limited to 5 minutes) and 

registration must be prior to close of 

business on November 3, 2010. It is 

requested that those who wish to have 

printed material distributed to the 

Committee provide thirty (30) copies of 

the document to the Executive 

Secretary, ACBSA, prior to close of 

business on November 3, 2010. If it is 

not possible to provide 30 copies of the 

material to be distributed, then 

individuals are requested to provide at 

a minimum one (1) copy of the 

document(s) to be distributed prior to 

the close of business on November 3, 

2010. It also is requested that any 

member of the public who wishes to 

provide comments to the Committee 

utilizing electronic data projection 

submit the necessary material to the 

Executive Secretary prior to close of 

business on November 3, 2010. 

Electronic comments must adhere to 

disability accessibility guidelines 

(Section 508 compliance). 

Dated: September 28, 2010. 

Richard A. Henry, 

Deputy Executive Secretary, Advisory 

Committee on Blood Safety and Availability. 

[FR Doc. 2010–24735 Filed 10–1–10; 8:45 am] 

BILLING CODE 4150–41–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

Periodically, the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) will publish a summary of 

information collection requests under 

OMB review, in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

documents, call the SAMHSA Reports 

Clearance Officer on (240) 276–1243. 

Proposed Project: Evaluation of 

Pregnant and Postpartum Women 

(PPW) Program 

The Substance Abuse and Mental 

Health Services Administration 

(SAMHSA), Center for Substance Abuse 

Treatment (CSAT), is funding 11 fiscal 

year (FY) 2009 Services Grants for the 

Residential Treatment for Pregnant and 

Postpartum Women (PPW) Program. 

The purpose of the PPW Program is to 

provide cost-effective, comprehensive, 

residential treatment services for 

pregnant and postpartum women who 

suffer from alcohol and other drug use 

problems, and for their infants and 

children impacted by the perinatal and 

environmental effects of maternal 

substance use and abuse. 

Section 508 [290bb–1] of the Public 

Health Service Act mandates the 

evaluation and dissemination of 

findings of residential treatment 

programs for pregnant and postpartum 

women. This cross-site accountability 

assessment will assess project activities 

implemented for these services. 

CSAT is requesting approval for a 

total of 8,404 burden hours for this new 

data collection. CSAT is requesting 

approval for a total of 23 instruments. 

Of these 23 instruments, 18 instruments 

are client-level tools and 5 instruments 

are process-level tools. To examine the 

effectiveness and impact of the PPW 

program, the current design includes 

both client-level outcomes and process 

evaluation components. The purpose of 

the outcome evaluation component is to 

examine the extent to which grantees 

accomplish the five core goals specified 

by the PPW program request for 

applications (RFA). These goals include: 

• Decrease the use and/or abuse of 

prescription drugs, alcohol, tobacco, 

illicit and other harmful drugs (e.g., 

inhalants) among pregnant and 

postpartum women; 

• Increase safe and healthy 

pregnancies; improve birth outcomes; 

and reduce related effects of maternal 

drug abuse on infants and children; 

• Improve the mental and physical 

health of the women and children; 

• Improve family functioning, 

economic stability, and quality of life; 

and 

• Decrease involvement in and 

exposure to crime, violence, sexual and 

physical abuse, and child abuse and 

neglect. 

In order to help interpret client-level 

outcomes, the process evaluation will 

explore what grantees are actually 

doing, how well they are doing it, any 

challenges encountered, and strategies 

grantees used to address them. 

Data collection instruments will be 

used to collect outcome and process 

data for this cross-site accountability 

evaluation, program and treatment 

planning, and local evaluations. For 

clients, data will be collected from 

women at four time points (intake, 6- 

months post-intake, discharge, and 6- 

months post-discharge), consistent with 

the GPRA data collection schedule. The 

schedule for collecting child data is 

similar to the mothers, with the addition 

of a 3-month post-intake time point. The 

following interview instruments will be 

used for women, fathers/mother’s 

partner, and children: 

Women Focused Tools 

• BASIS–24® (psychological 

symptomology). 

• Child Abuse Potential Inventory 

(overall risk for child physical abuse). 

• Ferrans and Powers Quality of Life 

Index (quality of life measure). 

• Family Support Scale (helpfulness 

of sources of support to parents raising 

a young child). 

• Women’s Discharge Tool (services 

received, length of stay, treatment goals 

achieved). 

• Staff Completed Women’s Items 

(pregnancy status, problems and 

outcomes). 

• Items Administered to Women 

(children residing with mother in 


jlentini on DSKJ8SOYB1PROD with NOTICES